What the FDA labels say about taking them together
Albuterol and levalbuterol
Levalbuterol's FDA label of December 10, 2025 names albuterol in its contraindications section; the albuterol labels PlainMeds reads (4) do not name levalbuterol. The levalbuterol label: “CONTRAINDICATIONS Levalbuterol Inhalation Solution, USP is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol.”
Check it at the source: the albuterol FDA label on DailyMed (effective April 30, 2026, Ritedose Pharmaceuticals, LLC); the levalbuterol FDA label on DailyMed (effective December 10, 2025, Ritedose Pharmaceuticals, LLC).
What does the albuterol label say about levalbuterol?
Albuterol's label (effective April 30, 2026) and its 3 other brand-application labels do not name levalbuterol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Albuterol Sulfate Inhalation Solution), Ritedose Pharmaceuticals, LLC, effective April 30, 2026 (SPL set d4c532be-1f41-60d3-e053-2995a90a98be), via openFDA; the full label on DailyMed
What does the levalbuterol label say about albuterol?
Levalbuterol label, contraindicationsCONTRAINDICATIONS Levalbuterol Inhalation Solution, USP is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol.
Levalbuterol label, drug interactionsMay potentiate effect of albuterol on the cardiovascular system. ( 7.5 ) See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Levalbuterol label, warnings and precautionsImmediate hypersensitivity reactions may occur after administration of levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema.
Xopenex Hfa label (Lupin Pharmaceuticals, Inc., June 2, 2025), contraindicationsCONTRAINDICATIONS XOPENEX HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of XOPENEX HFA. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema.
Xopenex Hfa label (Lupin Pharmaceuticals, Inc., June 2, 2025), drug interactionsMay potentiate effect of albuterol on the cardiovascular system.
Source: FDA drug label (Xopenex Hfa, NDA021730), Lupin Pharmaceuticals, Inc., effective June 2, 2025 (SPL set 70a35706-d7a8-4a48-98c6-1cab1c42fe8d), via openFDA
Source: FDA drug label (Levalbuterol), Ritedose Pharmaceuticals, LLC, effective December 10, 2025 (SPL set d6998949-e1cb-4c86-a480-c0dfd9cb75b5), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Albuterol | Levalbuterol | |
|---|---|---|
| Labeled for | Asthma | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.288 per tablet 2 mg tablet | $0.262 per mL 0.31 mg/3 mL solution |
| Shortage now | Resolved | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once